Special Issue "Advanced Transdermal Drug Delivery"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (30 December 2013)
Prof. Dr. Bozena B. Michniak-Kohn
Pharmaceutics, Ernest Mario School of Pharmacy; Center for Dermal Research (CDR) & Laboratory for Drug Delivery (LDD), NJ Center for Biomaterials, Life Sciences Building, Rutgers-The State University of New Jersey, 145, Bevier Road, Piscataway, NJ 08854, USA
Phone: +1 732 445 3589
Fax: +1 732 445 5006
Interests: topical; transdermal; percutaneous drug delivery; skin transport pathways; skin carrier systems; skin formulations; skin drug delivery; human skin equivalents; skin models
Transdermal delivery (TDD) systems offering a number of advantages over oral delivery have been available since 1979, when the first passive patch containing scopolamine was approved by the FDA. The future success of this dosage form is limited by the inability to deliver most drugs through the skin in therapeutically effective amounts. However, through novel designs of devices, new materials and active drug delivery approaches, we have the potential to significantly impact the future of TDD especially for those dosage forms containing macromolecules. Examples include microneedles, laser, ultrasound, iontophoresis and electroporation as well as thermal poration. In this “Advanced Transdermal Drug Delivery” Special Issue we will discuss the transdermal technologies of the future: the potential and the challenges.
Prof. Dr. Bozena B. Michniak-Kohn
Pharmaceutics (ISSN 1999-4923) is an Open Access journal, which is free to access and read on the Internet. MDPI guarantees that no university library or individual reader will ever have to buy a subscription or buy access through pay-per-view fees to access the articles published in the journal. Hence, MDPI does not have any income from selling subscriptions to the print or online version of this journal or from pay-per-view fees. In order to cover the costs of providing and maintaining a publication infrastructure, managing the journals, and processing the manuscripts through peer-review and the editorial procedure, the journal uses a form of conditional submission fee referred to as Article Processing Charge (APC).
For Pharmaceutics (ISSN 1999-4923), authors are asked to pay a fee of 500 CHF (Swiss Francs) per processed paper, but only if the article is accepted for publication in this journal after peer-review and possible revision of the manuscript. An additional fee of 250 CHF may apply for those articles that need major editing and formatting and/or English editing. Note that many national and private research funding organizations and universities explicitly cover such fees for articles originated in funded research projects. Discounts are available for authors from institutes that participate with MDPI's membership program.
In addition to Swiss Francs (CHF), we also accept payment of the fees in Euros (EUR), US Dollars (USD) or Chinese Yuan (CNY). Current exchange rates published at XE plus 5% exchange commission apply.
- transdermal delivery of macromolecules
- acoustical methods
- electric methods
- thermal poration
Article: Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses
Pharmaceutics 2014, 6(2), 220-234; doi:10.3390/pharmaceutics6020220
Received: 14 February 2014; in revised form: 21 April 2014 / Accepted: 25 April 2014 / Published: 15 May 2014| PDF Full-text (720 KB) | HTML Full-text | XML Full-text
Pharmaceutics 2014, 6(1), 52-77; doi:10.3390/pharmaceutics6010052
Received: 16 December 2013; in revised form: 24 January 2014 / Accepted: 11 February 2014 / Published: 28 February 2014| Cited by 2 | PDF Full-text (327 KB) | HTML Full-text | XML Full-text
Pharmaceutics 2013, 5(4), 634-651; doi:10.3390/pharmaceutics5040634
Received: 17 October 2013; in revised form: 7 December 2013 / Accepted: 10 December 2013 / Published: 16 December 2013| PDF Full-text (405 KB) | HTML Full-text | XML Full-text
Pharmaceutics 2013, 5(3), 434-444; doi:10.3390/pharmaceutics5030434
Received: 11 July 2013; in revised form: 14 August 2013 / Accepted: 14 August 2013 / Published: 21 August 2013| Cited by 2 | PDF Full-text (340 KB) | HTML Full-text | XML Full-text
Pharmaceutics 2013, 5(3), 385-391; doi:10.3390/pharmaceutics5030385
Received: 8 May 2013; in revised form: 1 July 2013 / Accepted: 3 July 2013 / Published: 11 July 2013| PDF Full-text (4025 KB) | HTML Full-text | XML Full-text
Last update: 9 September 2013